All In Biotech

Drug Trial Radar · NCT02120924

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea

A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference Listed Finacea® (Azelaic Acid) Gel, 15% in Patients With Moderate Facial Rosacea.

Last checked: Nov 19, 2026Latest source record: Jun 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,009 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,009

Actual

Start

Jul 2013

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Apr 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of moderate facial rosacea.

Conditions

  • Rosacea

Interventions

  • Azelaic acidDrug

    Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.

  • VehicleDrug

    Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.

  • FinaceaDrug

    Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts.Time frame: Baseline to Week 12

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Site 24

    Fremont, California

  • Site 22

    Santa Monica, California

  • Site 1

    Brandon, Florida

  • Site 3

    Fort Myers, Florida

  • Site 27

    Jacksonville, Florida

  • Site 19

    Miami, Florida

  • Site 9

    Miami, Florida

  • Site 29

    Miramar, Florida

  • Site 2

    Tampa, Florida

  • Site 15

    Chicago, Illinois

  • Site 4

    Plainfield, Indiana

  • Site 14

    Lake Charles, Louisiana

  • Site 17

    Glenn Dale, Maryland

  • Site 6

    Bay City, Michigan

  • Site 30

    Clinton Township, Michigan

  • Site 16

    Las Vegas, Nevada

  • Site 11

    Raleigh, North Carolina

  • Site 23

    Winston-Salem, North Carolina

  • Site 26

    Philadelphia, Pennsylvania

  • Site 12

    Warwick, Rhode Island

  • Site 28

    Simpsonville, South Carolina

  • Site 20

    Nashville, Tennessee

  • Site 21

    College Station, Texas

  • Site 5

    Dallas, Texas

  • Site 8

    El Paso, Texas

  • Site 13

    Houston, Texas

  • Site 7

    Katy, Texas

  • Site 18

    Salt Lake City, Utah

  • Site 10

    Norfolk, Virginia

  • Site 25

    University Place, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.